

TecSalud begins clinical trial of COVID antibody treatment



The pharmaceutical company [Inosan Biopharma](#), a world leader in antibody-based treatments, and [TecSalud's](#) Clinical Research department have formed a partnership in order to carry out **clinical trials of a new alternative for COVID-19 patients.**

The aim of these clinical trials is to examine whether **polyclonal antibodies** have the ability to **neutralize the virus and gradually eliminate it from the body** before the occurrence of complications that require hospitalization.

Polyclonal antibodies are a complex mixture of several antibodies produced from copies of B lymphocytes.

The clinical trial included in this partnership consists of an **antibody (immunoglobulin) therapy**, which goes through a process of fractioning and purification for later conversion into a pharmaceutical.

This drug will be administered to patients diagnosed with COVID-19 in order **to prevent as many hospitalizations as possible.**



width="900" loading="lazy">

A polyclonal antibody alternative to tackle the pandemic

For **Guillermo Torre**, Rector of TecSalud and Vice President for Research at [Tecnológico de Monterrey](#), it is important to continue searching for **effective alternatives against this virus** to tackle the pandemic that we continue to face.

“In addition to continuing the evolution of [existing vaccines](#), TecSalud is preparing a new alternative for patients suffering from this disease.

“This development will provide us with a highly effective treatment, which we hope will quickly reach the vast majority of the public,” he added.

“This development will provide us with a highly effective treatment, which we hope will quickly reach the vast majority of the public.” - Guillermo Torre

This new treatment is based on an **antibody technology platform**, which has also been used for the development of several medicines.

These include the world famous **antivenoms** for snake bites and scorpion stings, which have saved many lives around the world.

This will be the first time it has been used in order to **neutralize a virus**.

As **Juan López**, CEO of Inosan Biopharma, explained:

*“We’re proud to be able to contribute through the Inosan Biopharma technology platform. We see this new treatment as one of the best options there are to **neutralize the virus in the early stages** of a disease that has infected millions of people worldwide.”*



width="900" loading="lazy">

A Mexican collaboration to benefit society

This protocol is the result of the combined efforts of **TecSalud** and **Inosan Biopharma**, said Torre. It will also be a **100% Mexican collaboration** that benefits society and will boost Mexico’s medical and scientific ecosystem.

These clinical trials can begin now that **Cofepris** has approved **clinical trials of polyclonal antibodies** to treat COVID-19 patients in Mexico.

Inosan Biopharma has a proven track record of providing **safety and efficacy** in the products it has launched around the world. As a result, it has set a global benchmark for high production standards.

TecSalud provides **innovation and excellence** by conducting research aimed at transforming Mexican healthcare. It is currently participating in **several clinical research protocols** to tackle **COVID-19**.

Watch the presentation about the clinical trial here (in Spanish):

{"preview_thumbnail":"/sites/default/files/styles/video_embed_wysiwyg_preview/public/video_thumbnails/X
Video (Adaptable, autoplaying)."}}

READ MORE:

<https://tec.mx/en/news/national/health/covid-vaccines-characteristics-and-differences>